Retatrutide as the Reference Triple Agonist Retatrutide is the first triple agonist peptide to reach Phase 2 and Phase 3 clinical trials, and remains the reference compound for the category
Semaglutide is a medication gaining attention for its potential in weight loss management
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has gained significant attention for weight management beyond its original diabetes indication
NSL literature pointer PMID 16024700 L-Carnitine laboratory index [PMID: 16024700] National Science Labs indexing note for PMID 16024700: review the PubMed methods, models, and limitations before citing
Uses and Indications Byetta is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
for replenishment of electrolytes, trace elements, energy, protein and vitamins for athletes or convalescent animals It is a restorer of internal medium for the replacement and/or the maintenance of lost electrolytes during the exercise, training or competitions, dehydration, diarrheas, convalescences, loss or accentuated diminution of appetite, etc